Información del producto
- Ubrelvy
- Spiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1′,2′,5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxo-, (3′S)-
- (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide
- MK 1602
Ubrogepant is a small-molecule drug that is used to treat migraine. It inhibits the activity of a receptor called CGRP, which is associated with the development of migraine headaches. Ubrogepant has been shown to be effective in treating chronic cough and has also been found to be safe for long-term use. The drug does not have significant toxicity or major side effects. Ubrogepant may increase the risk of bleeding and gastrointestinal disorders when used with nonsteroidal anti-inflammatory drugs (NSAIDs).
Propiedades químicas
Consulta técnica sobre: 3D-FU165699 Ubrogepant
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
